Decisions relating to hospital medicines funding
24 April 2013
PHARMAC is pleased to announce that a further decision has been made to establish a nationally-consistent list of medicines to be funded within DHB hospitals. This decision relates to a consultation letter dated 19 November 2012.
These decisions establish a further four (of sixteen) ‘therapeutic groups’ that will make up the list of medicines to be funded in DHB hospitals, which will be contained in Section H of the Pharmaceutical Schedule: Dermatologicals, the Genito-Urinary System, Hormone Preparations and the Nervous System.
Details of the decision
Following consultation, some changes were made to the proposal. Additional items to be listed in Section H are:
- methohexital (methohexitone);
- betamethasone sodium phosphate injection and tablets;
- prilocaine with felypressin dental cartridges;
- mepivacaine dental cartridges;
- cocaine with adrenaline paste;
- additional presentations of fentanyl (20 mcg per ml, 100 ml bag; 10 mg per ml, 10 ml syringe);
- sucrose 25% oral liquid;
- an additional presentation of ketamine (4 mg per ml, 50 ml syringe);
- additional presentations of bupivacaine with fentanyl (bupivacaine 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag; bupivacaine 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe)
- a 15% strength of cocaine solution;
- an additional presentation of morphine sulphate (1 mg per ml, 2 ml syringe); and
- additional presentations of pethidine (10 mg per ml, 100 ml bag; 5 mg per ml, 10 ml syringe).
Other than these changes, the decision broadly reflects what was proposed in the consultation document.
Last updated: 8 March 2016